Index

Acquired prion disease: iatrogenic CJD, variant CJD, kuru: **Will RG**, 255–65
Aetiology of human prion diseases, 242–3
Aguzzi A, Heppner FL, Heikenwalder M, Prinz M, Mertz K, Seeger H, Glatzel M: Immune system and peripheral nerves in propagation of prions to CNS, 141–59
Animal models
  experimental, 9–10
  subclinical prion infection, 164–6
Animal TSE diseases, 7–9
Anonymous population screening (tonsils and appendix studies), 310–13
Anti-apoptotic molecule Bcl-2, 62, 66
Antioxidant activity, 65
Appendix studies, screening for preclinical vCJD, 310–13
Approaches to prophylaxis and therapy: **Dormont D**, 281–92

Beck JA *see* **Wadsworth JDF**
Behrens A: Physiological and pathological functions of the prion protein homologue Dpl, 35–42
Beta-sheet breakers, 286–7
Biochemistry and structure of PrP^{C} and PrP^{Sc}: **Riesner D**, 21–33
Biology of prion infection, 141–2
Blood product safety testing in sheep, 181
Blood-associated risks for medical personnel and patients, 297–8
Bovine spongiform encephalopathy (BSE) and its epidemiology: **Smith PG, Bradley R**, 185–98
Bovine spongiform encephalopathy (BSE), 8
Bradley R *see* **Smith PG**
Brandner S: CNS pathogenesis of prion diseases, 131–9
Bruce ME: TSE strain variation, 99–108
BSE (experimental) and scrapie in sheep : **Hunter N**, 171–183
Budka H: Neuropathology of prion diseases, 121–30

Calnexin (Clx), 62
Calreticulin, 62
Caughey B: Prion protein conversions: insight into mechanisms, TSE transmission barriers and strains, 109–20
Cell biology of mutant PrP, 75–7
Cell survival role for PrP^{C}, 66
Cellular
  cultures, TSE agent replication, 88
  localisation of PrP, 62
  trafficking of PrP, 71–4
Central surgical sterilization departments (CSSDs), 299–300
Cervid TSE, 1
Chaperones, 62–3
Chemical properties of PrP, 22–6
Chen SG *see* **Gambetti P**
Chesebro B: Introduction to the transmissible spongiform encephalopathies or prion diseases, 1–20
Chlorpromazine and quinacrine, 288
Chronic wasting disease (CWD) 1, 8–9, 112, 201–8
Classification (molecular and clinical) of human prion disease, 241–54
Classification and characterisation, of sporadic and familial CJD, 213–39
Clinical features of human prion diseases, 243–7
  and epidemiology, 305–7
  vCJD, 259–60
Clinical target areas, 135–137
Cenral nervous system (CNS)
  pathogenesis of prion diseases: **Brandner S**, 131–9
  immune system and peripheral nerves in propagation of prions to, 141–59
Codon 129, 305–6, 310
Collinge J *see* **Wadsworth JDF**
Colour plate section, v–xx
Conformational transitions of PrP, 29–
Congo Red, 286–7
Control measures
  animal health, and their impact, 189–91
  to protect human health, 193–6
Conversions of prion proteins: insight into mechanisms, TSE transmission barriers and strains, 109–20
Copper binding to PrP^{C}, 64–5
Corneal grafts and depth electrodes (EEG), 243, 256

British Medical Bulletin 2003; **65**: 317–321
DOI 10.1093/bmb/ldg66.317

© The British Council 2003

Creutzfeldt-Jakob disease (CJD), *ubique*
  ethical issues, 305–16
Crozet C *see* **Solassol J**
Cultured cells, prion propagation in, 87–97
CWD *see* Chronic wasting disease

Diagnosis of prion diseases: **Kübler E, Oesch B, Raeber AJ**, 267–79
  classical, 268–70
  molecular, 270–7
  overview, 267–8
  pre-implantation genetic (PGD) for inherited prion disease, 309
Doppel (Dpl) – prion protein homologue,
  identification of, 35–6
  expression, 36–7
  function in prion disease, 38–9
  and neuronal cell death, 37–8
  molecular basis of PrP antagonism, 38
  physiological function of, 39–40
Dormont D: Approaches to prophylaxis and therapy, 281–92
Drug screening, models for, 284–5
Dura mater grafts, contamination, 243, 256–7

Ectopic expression of PrP transgenes, 54–5
Elliott CL *see* **Tabrizi SJ**
Embryonic stem (ES) cell line, 48
Entry sites of prions, 142–3
Epidemiology
  and clinical features of human prion diseases, 305–7
  of BSE, 185–98
  vCJD, 260–3
Ethical issues in human prion diseases: **Tabrizi SJ, Elliott CL, Weissmann C**, 305–316
Experimental TSE therapy, 285–9
Experimentation on human subjects, ethical issues, 313–15

Familial and sporadic CJD – classification and characterisation, 213–39
Familial TSEs, 7
Fatal familial insomnia (FFI), 232–233
  clinical features, 245–6
  ethical issues, 305–6
  immunohistochemistry, 125, 127
  see also Sporadic fatal insomnia (sFI)
FDCs see Follicular dendrite cells
Feline spongiform encephalopathy (FSE), 199–201

Fixed tissues, TSE-related safety with regard to, 300–1
Flechsig E *see* **Weissmann C**
Flupirtine, 289
Follicular dendrite cells (FDCs), 54–5
  neuroinvasion, 282, 283, 286
  propagation of prions, 141–59

Gambetti P, Kong Q, Zou W, Parchi P, Chen SG: Sporadic and familial CJD – classification and characterisation, 213–39
Gene replacement and transgenesis, 47–9
Genetic screening (population) for codon 129 (vCJD-associated), 310–13
Genetic testing for inherited human prion diseases, ethical issues, 307–10
Gerstmann-Sträussler-Scheinker (GSS) syndrome, 43, *ubique*
    clinical features, 245–6
    ethical issues, 297, 305–6, 308
Glatzel M *see* **Aguzzi A**
Glial fibrillary acidic protein (GFAP), 54, 62
Glycosaminoglycans (GAGs), 67
Glycosylphosphatidylinositol (GPI), 2, 43, 110, 115–6
Growth hormone (hGH), 258–9
Gut and prions, 143–4

Harris DA: Trafficking, turnover and membrane topology of PrP, 71–85
Heikenwalder M *see* **Aguzzi A**
Heparin sulphate
  interactions with PrP, 63
  proteoglycans (HSPGs), 287
Heppner FL *see* **Aguzzi A**
Hill AF *see* **Wadsworth JDF**
Hill AF, Collinge J: Subclinical prion infection in humans and animals, 161–70
Histopathology of humen prion diseases, 122–4
History of transmission of prion diseases, 2–3
Human TSE diseases, summary, 3–7
Humoral immunity against prions, 153–4
Hunter N: Scrapie and experimental BSE in sheep, 171–183
Huntington's disease, 307–8
Hypoxanthine phosphoribosyl transferase (HPRT), 48

Iatrogenic CJD, 3–4, 244, 255–259, 305–7, 313

Immune system and peripheral nerves in propagation of prions to CNS: **Aguzzi A, Heppner FL, Heikenwalder M, Prinz M, Mertz K, Seeger H, Glatzel M**, 141–59
Immunization, PrP, 154–5
Immunohistochemistry for the prion protein (PrP), 124–7
Inactivation methods, 298–300
Incubation period, influence of TSE strain on, 100–1
Infectious agent, theories of, 11–15
  viral hypothesis, 11–14
  protein-only hypothesis, 14–15
Inherited prion diseases, 244, 245–6
  transgenic mouse models, 53
Inhibitors of conversion as TSE therapeutic agents, 117
Innate immunity and antiprion defence, 152–3
Introduction to the transmissible spongiform encephalopathies or prion diseases: **Chesebro B**, 1–20
Iododoxorubicin, 286–7

Knock-out (PrP) mice, 44–7
Kong Q *see* **Gambetti P**
Kübler E, Oesch B, Raeber AJ: Diagnosis of prion diseases, 267–79
Kuru, 3–4, 163–4, 259, 262–4, 305–6, 308
  clinical features, 246

Laminin receptor precursor (LRP), 62, 67, 287
Lasmézas CI: Putative functions of PrPC, 61–70
Lehmann S *see* **Solassol J**
Lymphocytes and prions, 144–5
Lymphoreticular system (LRS) infection, 59, 295, 297–9
Lymphoreticular tissues and vCJD, 167

Macroscopy of human prion diseases, 121–2
Meat-and-bone-meal (MBM), 186–8
Mechanically recovered meat (MRM), 294,310
Mechanisms (prion protein conversions: insight into), TSE transmission barriers and strains, 109–20
Meissner and Auebach plexuses, 282
Membrane topology, turnover and trafficking of PrP, 71–85
Mertz K *see* **Aguzzi A**
Mice devoid of PrP, generatoon and properties, 43–7
Miller MW *see* **Sigurdson CJ**
Mink (transmissible) encephalopathy (TME), 162, 208–10
Models for drug screening, 284–5
Molecular and clinical classification of human prion disease: **Wadsworth JDF, Hill AF, Beck JA, Collinge J**, 241–54
  classification of human prion diseases, 247–50
  diagnosis of vCJD, *ante-mortem* tonsil biopsy, 250–1

Neurodegeneration mechanismsin prion diseases, 131–139
Neuro-invasion by prions, 149–51
Neuronal death modulators, 288–9
Neuronal-specific enolase (NSE), 55, 245
Neuropathology of prion diseases: **Budka H**, 121–30
  influence of TSE strain on, 101–2
Neurosurgical transmission, 243, 256

Oesch B *see* **Kübler E**
Other animal prion diseases: **Sigurdson CJ, Miller MW**, 199–212

Parchi P *see* **Gambetti P**
Pathogenesis (CNS) of prion diseases, 131–9
Pathogenetic contribution, 127
Pathological and physiological functions of the prion protein homologue Dpl, 35–42
Pathological mouse phenotypes elicited by PrP mutations, 52–4
Periodic sharp wave (PSW) complexes 216, 220–1, 223–4, 228–34
Peripheral nerves and immune system in propagation of prions to CNS, 141–59
Person-to-person transmission of TSEs, 294–7
Physiological and pathological functions of the prion protein homologue Dpl: **Behrens A**, 35–42
Pituitary hormones, human, 258–9
Polyene antibiotics, 287–8
Predictive genetic testing for inherited prion disease, 307–8
Pre-implantation genetic diagnosis (PGD), 309
Prenatal testing for inherited prion disease, 308–10

Preventing accidental transmission of human transmissible spongifom encephalopathies: **Taylor DM**, 293–303
Primates (non-human) and zoo ruminants and TSEs, 199–201
Prinz M *see* **Aguzzi A**
Prion propagation in cultured cells: **Solassol J, Crozet C, Lehmann S**, 87–97
Prion protein conversions: insight into mechanisms, TSE transmission barriers and strains: **Caughey B**, 109–20
Prion
  diseases, introduction to, 1–20
  receptor (PrR), 63, 66–7
  reservoirs in periphery of the body, 146–8
  strains
    and lymphotropism, 145–6, 148–9
    transmission barriers, 162–3
Prion-infected cell-culture models, 93
Propagation of prions
  in cultured cells, 87–97
  immune system and peripheral nerves in, to CNS, 141–59
Prophylaxis and therapy (human), 281–92
Proteasome, role of, in metabolism of PrP, 77–9
Protein misfolding cyclic amplification (PMCA), 111, 116
Protein-only hypothesis, 14–15
PrP knock-out and PrP transgenic mice in prion research: **Weissmann C, Flechsig E**, 43–60
PrP mutations, effect on health and prion disease in mice, 49–52
PrP^{C} interacting molecules, 62–3
Putative functions of PrP^{C}: **Lasmézas CI**, 61–70

Quinacrine and chlorpromazine, 288

Raeber AJ *see* **Kübler E**
Randomised control therapy in human prion disease, ethics, 313–15
Reactive oxygen radicals (ROR), 283, 288
Recombinant PrP, chemical properties, 22–6
Resistance to scrapie, PrP knock-out mice, 45–7, 50
Riesner D: Biochemistry and structure of PrP^{C} and PrP^{Sc}, 21–33
Risks to public health of subclinical prion infection, 166–7
Rocky Mountain Laboratory (RML), 90, 134

Scrapie and experimental BSE in sheep: **Hunter N**, 171–183 (also 7–8)
Seeger H *see* **Aguzzi A**
Sheep, scrapie and experimental BSE in, 171–83
Signalling function of PrP^{C}, 65–7
Sigurdson CJ, Miller MW: Other animal prion diseases, 199–212
Skin and prions, 144
Smith PG, Bradley R: Bovine spongiform encephalopathy (BSE) and its epidemiology, 185–98
Solassol J, Crozet C, Lehmann S: Prion propagation in cultured cells, 87–97
Species barrier, 9–10
  effects of PrP mutations, 51–2
Specific risk materials (SRM) ban, 193–6
Specified bovine offal (SBO), 194
Spongiform Encephalopathy Advisory Committee (SEAC), 195
Sporadic and familial CJD
  – classification and characterisation: **Gambetti P, Kong Q, Zou W, Parchi P, Chen SG**, 213–39
Sporadic CJD (sCJD), 244–5, 260–3, 282
  subtypes, 213–39
  ethical issues, 305–7
Sporadic fatal insomnia (sFI) and FFI, 213, 215–27, 224–5, 232–233
  ethical issues, 305–6
Sporadic TSE, 6–7
Spread of prions within CNS, 151–2
Strain typing of natural TSEs, 103–6
Strain variation in TSEs, 15–16, 99–108
  implication, 106–7
  and transmission barriers (TSE), 109–20
Structure (membrane) of PrP, 71–85
Structure of and biochemistry of PrP^{C} and PrP^{Sc}: **Riesner D**, 21–33
Subclinical prion infection in humans and animals: **Hill AF, Collinge J**, 161–70
Subtypes of sporadic CJD, 213–39
Superoxide dismutase, 65
Sympathetic nerves: a neuro-immune synapse for prions?, 149–51
Synapsin Ib, 62
Synatic function, 63–4

Taylor DM: Preventing accidental transmission of human transmissible spongifom encephalopathies, 293–303
Tetracycline, 286–7
Therapeutic agent testing in sheep, 181

Therapies, rationale for, aiming at a reduction of PrP expression, 137
Therapy (TSE)
and prophylaxis (human), 281–92
scientific background to, 281–4
Tonsil biopsy, *ante-mortem* molecular diagnosis of vCJD, 167, 250–1
screening for preclinical vCJD, 310–13
Trafficking, turnover and membrane topology of PrP: **Harris DA**, 71–85
Transgenesis and gene replacement, 47–9
Transgenic mice models of
familial human TSE disease, 10–11
inherited prion diseases, 53
Transmembrane PrP, 79–82
Transmissible spongiform encephalopathies (TSE), 1–20
strain variation: **Bruce ME**, 99–108
Transmissible mink encephalopathy (TME), 9, 162, 208–10
Transmission (potential) iatrogenic vCJD prions, 251–2
Transmission barriers and prion strains, 109–20, 162–3
Transmission of human TSEs, preventing accidental, 293–303
TSE *see* transmissible spongiform encephalopathies

Variant CJD (vCJD) in humans, 4–6, 259–63
background to therapy, 281–4
clinical features, 246–7
ethical issues and screening, 305-16
and scrapie in sheep, 171–83
transmission prevention, 293–9
Viral hypothesis, 11–14
Von Hippel-Lindau disease, 307

Wadsworth JDF, Hill AF, Beck JA, Collinge J: Molecular and clinical classification of human prion disease, 241–54
Weissmann C *see also* **Tabrizi SJ**
Weissmann C, Flechsig E: PrP knock-out and PrP transgenic mice in prion research, 43–60
Will RG: Acquired prion disease: iatrogenic CJD, variant CJD, kuru, 255–65

Zoo ruminants and non-human primates and TSEs, 199–201
Zou W *see* **Gambetti P**